Biomedical Research Service


  • Google
Home
Citations
Metabolites
Enzymes
Recipes
Contact Us
Order

Pyruvate Dehydrogenase Assay Kit



(PDH Assay Kit)



Product Description:

Pyruvate is the end product of aerobic glycolysis and is at an important metabolic crossroad. The pyruvate dehydrogenase multi-enzyme complex (PDH) catalyzes the oxidative decarboxylation of pyruvate to acetyl-CoA in a series of reactions mediated by the E1 subunit (pyruvate dehydrogenase), E2 subunit (dihydrolipoyl transacetylase), and E3 subunit (dihydrolipoyl dehydrogenase). The reactions of the PDH complex serve to interconnect the metabolic pathways of glycolysis, gluconeogenesis and fatty acid synthesis to the Krebs (TCA) cycle. As a consequence, the PDH complex is highly regulated by a variety of allosteric effectors and by covalent modification. The importance of the PDH complex in metabolic regulation is evident from the fact that although diseases associated with deficiencies of the PDH complex have been observed, affected individuals often do not survive to maturity. This non-radioactive colorimetric PDH assay is based on the reduction of the tetrazolium salt INT in a NADH-coupled enzymatic reaction to formazan, which is water-soluble and exhibits an absorption maximum at 492 nm. The intensity of the red color formed is increased in the presence of increased PDH activity. The kit is stable for at least one year under proper storage and handling conditions.

#Pyruvate Dehydrogenase


Kit Components:

PDH Assay Solution: 5 ml (100 wells), store at -80ºC

10x Cell Lysis Solution: 25 ml, store at 4ºC


SDS:

TX-100, DMSO, INT, acetic acid, Hepes


Related Kits:

HK Enzyme Assay, GAPDH Enzyme Assay, LDH Enzyme Assay, L-Lactate Assay, Glucose Assay, Pyruvate Assay, NAD+ Assay


Citation:

Eastlack et al

Suppression of PDHX by microRNA-27b deregulates cell metabolism and promotes growth in breast cancer

Molecular Cancer 17:100, 2018


Martin et al

Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer

Oncogene 36(4):525-533, 2017